Endocrine Today Current Issue

The following articles appeared in the print edition of Endocrine Today.

Table of Contents

• Trials intended for cardiovascular outcomes offer insight into diabetes therapies
• Acarbose noninferior to metformin in type 2 diabetes
• Endocrine Society, AACE release list of tests to avoid
• Medicare pays too much, not too little Richard O. Dolinar, MD
• FDA approves Duavee for treatment of menopausal symptoms, prevention of osteoporosis
• Adrenocortical carcinoma drug starts phase 1 trial, gains orphan drug status
• Hypersexuality, hirsutism and acne in a postmenopausal woman Stephanie L. Lee, MD, PhD, ECNU
• Adherence to diabetes treatment: Crucial, but challenging Edward C. Chao, DO
• Excessive pregnancy weight gain increased risk for obese offspring
• Exercise, drug interventions may produce similar outcomes on mortality
• GnRHa may depreciate anti-Müllerian hormone as ovarian reserve marker
• Higher BMI increased CVD mortality risk
• Higher carbohydrate intake may increase intracellular cortisol
• HPA axis recovered within 6 to 12 weeks of infant prednisolone therapy
• Hypertension screening urged for obese children
• Hypothalamic-pituitary disorders increased risk for fibromyalgia-associated symptoms
• Identical twins study sheds light on metabolically healthy obese
• Low-risk thyroid cancers overtreated due to ‘epidemic in diagnosis’
• MAGEL2 gene could contribute to symptoms of Prader-Willi syndrome, autism
• Many patients with type 1 diabetes have functioning beta cells, produce insulin
• Patients with Rett syndrome face severe vitamin D deficiency
• Poor diabetes management linked to adolescent depression
• Prediction rule estimated all-cause mortality risk before bariatric surgery
• Rosiglitazone/exenatide decreased adverse CV events in patients with diabetes
• SEQUEL: Phentermine-topiramate reduced incident type 2 diabetes by nearly 80%
• Diabetes increased risk for breast, colorectal cancers
• TERT promoter and BRAF mutation co-existence defines ‘most aggressive subgroup of PTC’
• Diabetes mellitus demonstrated as independent predictor of cirrhosis, hepatocellular carcinoma
• FREEDOM extension: Denosumab continued to improve BMD, prevent fractures
• Increased inflammatory markers point toward higher risk for hip fracture
• Low trabecular bone scores tied to increased vertebral fracture risk
• Maternal, congenital hypothyroidism affects brain development and cognitive ability
• MIVAP may be effective alternative for hyperparathyroidism
• MrOS: Calcium supplements did not increase risk for CV mortality
• Next-generation sequencing tool shows 96% specificity in thyroid cancer detection
• Severe obesity is a risk factor for virological failure
• RET, RAS mutations affected cabozantinib response in medullary thyroid cancer
• Risk for fracture tripled in men with sarcopenia and osteopenia/osteoporosis
• Rituximab outperformed steroids in Graves’ ophthalmopathy
• TERT promoter and BRAF mutation co-existence defines ‘most aggressive subgroup of PTC’